Brought to you by 
Ipsen buys Vernalis US subsidiary/Apokyn rights; later sells to Britannia
27 Apr 2021
Executive Summary
As part of a concentrated push to establish itself in the US specialty pharmaceuticals market, the French company Ipsen has acquired Vernalis PLC's American subsidiary Vernalis Pharmaceuticals Inc., plus the US license to the marketed Parkinson's drug Apokyn (apomorphine injection), for $13.7mm plus a potential $5mm earn-out.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen buys Vernalis US subsidiary/Apokyn rights; later sells to Britannia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice